Testing for Inhaled Insulin

Diabetics now have a new option thanks to the breakthrough new medication AFREZZA®, an inhaled insulin now available by prescription. 

The labeling for AFREZZA®, mandates spirometry testing (specifically FEV1) to rule out chronic lung disease prior to initiating therapy, six months after initiation and every year thereafter1. 

MD Spiro offers a number of spirometer options and the expertise to easily integrate spirometry into your practice. From the non-reimbursable, PulmoLife at $195 to the full featured MicroLab at $2,295, Micro Direct has a spirometer designed to meet your needs. 
 
American Thoracic Society (ATS) Coding Recommendations

To aid in the coding for spirometry testing, the ATS has determined the appropriate ICD-9 codes and CPT codes. The following table lists examples of how to record these diagnosis and billing codes:

Spirometry prior to initiation of therapy	94010*	V72.85 + code for underlying condition (diabetes) as additional diagnosis
Spirometry after first 6 months of therapy	94010*	V58.83 + V58.67 + code for underlying condition (diabetes) as additional diagnosis
Annual spirometry testing	94010*	V58.83 + V58.67 + code for underlying condition (diabetes) as additional diagnosis

* It may also be appropriate to append this code with the “-32” modifier indicating that the test is “mandated” by the FDA as part of the labeling restrictions for inhaled insulin.2

For additional information, call us today at 800-588-3381.

References:
a All Current Procedural Terminology (CPT) 5-digit number codes, descriptions, number modifiers, instructions, guidelines and other material are Copyright © 2014 American Medical Association. All rights reserved. 
1. This information is not a substitute for medical advice and does not provide a complete summary of AFREZZA® or any inhaled insulin product or address all considerations in making treatment decisions regarding their use. Always refer to the complete product information provided by the manufacturer. 
2. Modifier minute: modifier 32. American Academy of Professional Coders website. http://news.aapc.com/index.php/2013/04/modifier-minute. Accessed December 22, 2014. 

AFREZZA® is a registered trademark owned by MannKind Corporation. 
Micro Direct, Inc./MD Spiro is not sponsored by nor has any affiliation with Sanofi, US, Inc., MannKind or the AFREZZA® trademark.
https://boundbymarketingdev.com/mdspiro/for-your-practice 
https://boundbymarketingdev.com/mdspiro/microlab-spirometer
https://boundbymarketingdev.com/mdspiro/pulmolife